Latest News

Japan's filing covers IRDs broadly, supported by RESTORE and open-label Stargardt data.

Inherited metabolic diseases affect the retina even before the systemic diagnosis is established.

Sharon Fekrat, MD, FACS, FASRS, discusses how retinal imaging fits into the diagnostic picture for CVI, TBI, and neurodegenerative disease.

An industry symposium on intravitreal 4D-150 and a course on subretinal delivery lead gene therapy content at EURETINA 2026, alongside IRD courses and trial readouts.

Nimesh Patel, MD, urges the FDA to reconsider SYD-101 as pediatric myopia drives earlier retinal damage in US children.

Sequencing IOL choice by eye can ease patient decision paralysis.

Aldeyra Therapeutics will submit a FDRR to the FDA for reproxalap, an investigational drug or dry eye disease.

Coats, OD, FAAO, explains how neurotrophic keratitis, demodex, cosmetic habits and mucus fishing complicate dry eye disease.

Tarcocimab, tabirafusp-ted were noninferior to aflibercept in DAYBREAK wet AMD trial; 54% on tarcocimab reached 24-week dosing.

Study found anti-VEGF therapy was linked to kidney function decline in patients with diabetic retinopathy or retinal vein occlusion.

Non-invasive electrical stimulation delivered through closed eyelids improved retinal structure and photoreceptor function.

Jesse L. Berry, MD, discusses prospective data on aqueous humor liquid biopsy in retinoblastoma and explains how molecular markers from the aqueous are beginning to guide recurrence risk, treatment intensity, and the workup of otherwise diagnostically inaccessible intraocular lesions.

Concurrent exudative disease, early intervention, and a rare masquerader complicate the classic picture of geographic atrophy.